Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : RQ Bio
Deal Size : Undisclosed
Deal Type : Collaboration
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
Details : The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent anti...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : RQ Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : International Centre for Genetic Engineering and Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : International Centre for Genetic Engineering and Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production
Details : Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 15, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DPX-COVID-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company has used sequences of the virus and immunoinformatics to predict and has identified 23 epitopes for their potential to generate neutralizing antibodies against SARS-CoV-2.
Product Name : DPX-COVID-19
Product Type : Vaccine
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : DPX-COVID-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable